dc.contributor.author |
Schwalb Calderon, Alvaro |
|
dc.contributor.author |
Cachay Figueroa, Rodrigo Antonio |
|
dc.contributor.author |
Meza, E. |
|
dc.contributor.author |
Cáceres Nakiche, Tatiana |
|
dc.contributor.author |
Blackman, A. |
|
dc.contributor.author |
Maruri, F. |
|
dc.contributor.author |
Sterling, T.R. |
|
dc.contributor.author |
Gotuzzo Herencia, José Eduardo |
|
dc.date.accessioned |
2021-12-12T20:24:56Z |
|
dc.date.available |
2021-12-12T20:24:56Z |
|
dc.date.issued |
2021 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/10247 |
|
dc.description.abstract |
Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
BioMed Central |
|
dc.relation.ispartofseries |
BMC Research Notes |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Drug resistance |
en_US |
dc.subject |
Levofloxacin |
en_US |
dc.subject |
Moxifloxacin |
en_US |
dc.subject |
Ofloxacin |
en_US |
dc.title |
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1186/s13104-021-05832-0 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.05 |
|
dc.relation.issn |
1756-0500 |
|